|Table of Contents|

The correlation analysis of TAMs in different neoadjuvant regimens in locally advanced non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 19
Page:
3694-3699
Research Field:
Publishing date:

Info

Title:
The correlation analysis of TAMs in different neoadjuvant regimens in locally advanced non-small cell lung cancer
Author(s):
LI Suoni1; HUYAN Zhuoya2; MA Jiequn1; LIAO Zijun1; ZHANG Yanbing1
1.Department of Oncology,Shaanxi Provincial Tumor Hospital,Shaanxi Xi'an 710061,China;2.Rheumatology and Immunology Department,Xi'an No.3 Hospital,Shaanxi Xi'an 710021,China.
Keywords:
non-small cell lung cancer; neoadjuvant immunotherapy combined with chemotherapy; main pathological relief; tumor associated macrophages
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.19.012
Abstract:
Objective:Analysis of tumor-associated macrophages(TAMs) levels and efficacy correlation in different neoadjuvant regimens in locally advanced non-small cell lung cancer（NSCLC）.Methods:Collect 163 patients who received neoadjuvant therapy and surgical treatment at our hospital from January 1,2018 to June 30,2022.Divide them into two groups according to different neoadjuvant treatment regimens:Neoadjuvant immunotherapy combined with chemotherapy group and neoadjuvant chemotherapy group,and perform MPR calculation.And analyze the factors which affect MPR.At the same time,immunohistochemical staining of TAMs related molecules(CD68,CD86,CD163) was performed on 37 patients with pre-and post treatment paired specimens to analyze their correlation with clinical efficacy.Results:The MPR of the neoadjuvant immunotherapy combined with chemotherapy group was significantly higher than that of the neoadjuvant chemotherapy group (58.6% vs 21.3%,P＜0.001).In the neoadjuvant immunotherapy combined with chemotherapy group,the positive expression rate of CD86 after treatment was higher than before treatment (75% vs 16.7%,P=0.039).There was no significant difference in the expression levels of CD163 and CD68 before and after treatment (P＞0.05).In the neoadjuvant chemotherapy group,the positive expression rates of CD68 and CD86 after treatment were higher than before treatment (64% vs 28%,P=0.035) and (68% vs 28%,P=0.021).But the expression level of CD163 showed no significant difference before and after treatment (P＞0.05).There was no statistically significant difference in the expression of CD68,CD86,and CD163 between the neoadjuvant immunotherapy combined with chemotherapy and chemotherapy groups (P＞0.05).In addition,in the neoadjuvant immunotherapy combined with chemotherapy group,the changes in CD86 expression before and after treatment were positively correlated with MPR (rs=0.577,P=0.046).However,there was no significant correlation between the expression changes of CD68 and CD163 before and after treatment and MPR (P＞0.05).In the neoadjuvant chemotherapy group,there was no significant correlation between the expression changes of CD68,CD163,and CD86 before and after treatment and MPR (P＞0.05).Conclusion:Compared to neoadjuvant chemotherapy,neoadjuvant immunotherapy combined with chemotherapy can bring higher MPR rates to patients with locally advanced NSCLC that can be resectable.The changes in M1 type(CD86) TAMs can serve as potential biomarkers for predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy.

References:

［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］AUPERIN A,LE PC,ROLLAND E,et al.Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer［J］.J Clin Oncol,2010,28(13):2181-2190.
［3］MIAO D,ZHAO J,HAN Y,et al.Management of locally advanced non-small cell lung cancer:state of the art and future directions［J］.Cancer Commun(Lond),2024,44(1):23-46.
［4］TOPALIAN SL,FORDE PM,EMENS LA,et al.Neoadjuvant immune checkpoint blockade:A window of opportunity to advance cancer immunotherapy［J］.Cancer Cell,2023,41(9):1551-1566.
［5］FORDE PM,CHAFT JE,SMITH KN,et al. Neoadjuvant PD-1 blockade in resectable lung cancer［J］.N Engl J Med,2018,378(21):1976-1986.
［6］JIA XH,XU H,GENG LY,et al.Efcacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer:a Meta-analysis［J］.Lung Cancer,2020,147:143-153.
［7］TANG B,WANG Y,XU W,et al.Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer［J］.Cancer Lett,2023,554:216021-216038.
［8］SHU CA,GAINOR JF,AWAD M,et al.Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer:an open-label,multicentre,single-arm,phase 2 trial［J］.The Lancet Oncology,2020,21(6):786-795.
［9］PROVENCIO M,NADAL E,INSA A,et al.Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM):an open-label,multicentre,single-arm,phase 2 trial［J］.The Lancet Oncology,2020,21(11):1413-1422.
［10］FORDE PM,SPICER J,LU S,et al.Abstract CT003:Nivolumab (NIVO)+platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (Ⅰb-Ⅲa) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial［J］.Cancer Research,2021,81:CT003.
［11］陈思,赵泽锐,龙浩.新辅助免疫治疗及联合化疗在NSCLC中的研究进展［J］.中国肺癌杂志,2021,24(4):284-292. CHEN S,ZHAO ZR,LONG H.Research progress of neoadjuvant immunotherapy and combined chemotherapy in NSCLC［J］. Chinese Journal of Lung Cancer,2021,24(4):284-292.
［12］HEYMACH JV,HARPOLE D,MITSUDOMI T,et al.Design and rationale for a phase Ⅲ,bouble-blind,placebo-controlled study of neoadjuvant durvalumab+chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages Ⅱ and Ⅲ non-small-cell lung cancer:The AEGEAN trial［J］.Clin Lung Cancer,2022,23(3):e247-e251.
［13］FORDE PM,SPICER J,LU S,et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer［J］.N Engl J Med,2022,386(21):1973-1985.
［14］FELIP E,ALTORKI N,ZHOU C,et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage Ⅰb-Ⅲa non-small-cell lung cancer (IMpower-010):a randomised,multicentre,open-label,phase 3 trial［J］.Lancet,2021,398(10308):1344-1357.
［15］O'BRIEN M,PAZ-ARES L,MARREAUD S,et al.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage Ⅰb-Ⅲa non-small-cell lung cancer:an interim analysis of a randomised,triple-blind,phase 3 trial［J］.Lancet Oncol,2022,23(10):1274-1286.
［16］JAYASINGAM SD,CITARTAN M,THANG TH,et al.Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue:technicalities and challenges in routine clinical practice［J］.Front Oncol,2020,24(9):1512.
［17］LIN Y,XU J,LAN H.Tumor-associated macrophages in tumor metastasis:biological roles and clinical therapeutic applications［J］.J Hematol Oncol,2019,12(1):76-82.
［18］LIU R,HU R,ZENG Y,et al.Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes:a gene expression-based computational study［J］.EBioMedicine,2020,51:102602-102616.
［19］ROMANO E,KUSIO-KOBIALKA M,FOUKAS PG,et al.Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients［J］.Proc Natl Acad Sci USA,2015,112(19):6140-6145.
［20］PIAO H,FU L,WANG Y,et al.A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression［J］.J Exp Clin Cancer Res,2022,41(1):174-191.
［21］CAO L, CHE X,QIU X,et al.M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer［J］.Cancer Management and Research,2019,11:6125-6138.
［22］SUMITOMO R,HIRAI T,FUJITA M,et al.M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer［J］.Experimental and Therapeutic Medicine,2019,18(6):4490-4498.

Memo

Memo:
陕西省重点研发计划基金资助项目（编号：2022SF282）
Last Update: 2024-08-30